肝癌肝切除围手术期管理中国专家共识(2021年版)

2021-04-30 中华肿瘤杂志.2021.43(4):414-430.

肝切除术是肝癌最主要的根治性治疗手段。肝脏解剖结构复杂、血供丰富,手术难度大,但随着手术设备的不断升级以及手术技术的发展,目前多数治疗中心的围手术期死亡率<5%。然而,肝切除术后并发症发生率仍然高达1

中文标题:

肝癌肝切除围手术期管理中国专家共识(2021年版)

发布机构:

发布日期:

2021-04-30

简要介绍:

肝切除术是肝癌最主要的根治性治疗手段。肝脏解剖结构复杂、血供丰富,手术难度大,但随着手术设备的不断升级以及手术技术的发展,目前多数治疗中心的围手术期死亡率<5%。然而,肝切除术后并发症发生率仍然高达15%~50%,如何进一步降低术后并发症的发生率是目前亟待解决的临床问题。为了规范肝切除围手术期管理,肿瘤防治专家委员会特邀请国内不同领域专家,以原发性肝癌诊疗规范(2019 年版)为指导,结合国内肝癌诊疗特点,遵循加速康复外科理念,修订并更新形成肝癌肝切除围手术期管理中国专家共识(2021 年版)。

 

下载附件:

(因为版权问题,不支持下载)

评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1227134, encodeId=ee85122e134e4, content=临床指导工作, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f881504026, createdName=yanlingqun700101, createdTime=Sat Jun 18 01:07:21 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200255, encodeId=6661120025552, content=好,指导性强, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78986481430, createdName=ms2000001319554899, createdTime=Mon Mar 07 16:22:33 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180203, encodeId=8c751180203fe, content=嗯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:30:07 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180202, encodeId=ad82118020263, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:29:07 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180201, encodeId=87e11180201e9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:28:53 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
    2022-06-18 yanlingqun700101

    临床指导工作

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1227134, encodeId=ee85122e134e4, content=临床指导工作, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f881504026, createdName=yanlingqun700101, createdTime=Sat Jun 18 01:07:21 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200255, encodeId=6661120025552, content=好,指导性强, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78986481430, createdName=ms2000001319554899, createdTime=Mon Mar 07 16:22:33 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180203, encodeId=8c751180203fe, content=嗯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:30:07 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180202, encodeId=ad82118020263, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:29:07 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180201, encodeId=87e11180201e9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:28:53 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
    2022-03-07 ms2000001319554899

    好,指导性强

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1227134, encodeId=ee85122e134e4, content=临床指导工作, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f881504026, createdName=yanlingqun700101, createdTime=Sat Jun 18 01:07:21 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200255, encodeId=6661120025552, content=好,指导性强, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78986481430, createdName=ms2000001319554899, createdTime=Mon Mar 07 16:22:33 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180203, encodeId=8c751180203fe, content=嗯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:30:07 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180202, encodeId=ad82118020263, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:29:07 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180201, encodeId=87e11180201e9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:28:53 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
    2022-01-03 ms6000001939075812

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1227134, encodeId=ee85122e134e4, content=临床指导工作, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f881504026, createdName=yanlingqun700101, createdTime=Sat Jun 18 01:07:21 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200255, encodeId=6661120025552, content=好,指导性强, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78986481430, createdName=ms2000001319554899, createdTime=Mon Mar 07 16:22:33 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180203, encodeId=8c751180203fe, content=嗯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:30:07 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180202, encodeId=ad82118020263, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:29:07 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180201, encodeId=87e11180201e9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:28:53 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
    2022-01-03 ms6000001939075812

    很好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1227134, encodeId=ee85122e134e4, content=临床指导工作, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f881504026, createdName=yanlingqun700101, createdTime=Sat Jun 18 01:07:21 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200255, encodeId=6661120025552, content=好,指导性强, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78986481430, createdName=ms2000001319554899, createdTime=Mon Mar 07 16:22:33 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180203, encodeId=8c751180203fe, content=嗯, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:30:07 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180202, encodeId=ad82118020263, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:29:07 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180201, encodeId=87e11180201e9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3e5497618, createdName=ms6000001939075812, createdTime=Mon Jan 03 22:28:53 CST 2022, time=2022-01-03, status=1, ipAttribution=)]
    2022-01-03 ms6000001939075812

    0